Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.52 |
| ▸ | RAB9A | P51151 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | CCR5 | P51681 | 2/20 | 0.48 |
| ▸ | CCR8 | P51685 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.48 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2900102 | 0.75 | CYP19A1 (0.36) | CYP19A1 | |
| SCHEMBL679517 | 0.73 | HDAC1 (0.40) | KDM4ECYP1A2POLBALDH1A1HSD17B10 | |
| SCHEMBL315880 | 0.71 | PDPK1 (0.43) | KDM4ERAB9ANPC1POLBALDH1A1 | |
| Dipyridyl SCHEMBL7076471 | 0.71 | KDM4E (0.93) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL452340 | 0.69 | KDM4E (0.57) | KDM4ERAB9ANPC1MAPTATM | |
| SCHEMBL1424929 | 0.69 | KDM4E (1.00) | KDM4ERAB9ANPC1MAPTATM | |
| Dipyridyl SCHEMBL29351528 | 0.68 | KDM4E (1.00) | KDM4ERAB9ANPC1MAPTATM | |
| Dipyridyl SCHEMBL29907716 | 0.68 | KDM4E (1.00) | KDM4ERAB9ANPC1MAPTATM | |
| Dipyridyl SCHEMBL3711450 | 0.68 | KDM4E (1.00) | KDM4ERAB9ANPC1MAPTATM | |
| Dipyridyl SCHEMBL5922 | 0.68 | KDM4E (1.00) | KDM4ERAB9ANPC1MAPTATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343797-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-09-20 | — | — | EP | claimed |
| CN-1829721-A | Spiro '1-azabicyclo' 2.2.2! octan-3,5'-oxazolidin - 2'-one! derivatives with affinity to the alpha7 nicotinic acetylcholine receptor | ASTRAZENECA AB (SE) | 2006-09-06 | — | — | CN | claimed |
| US-6900183-B2 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2005-05-31 | — | — | US | claimed |
| US-20040082526-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-29 | — | — | US | claimed |
| EP-1343797-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | claimed |
| WO-2002050092-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | claimed |
| US-5470862-A | Intravenous anesthetics | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1995-11-28 | — | — | US | claimed |
| US-20230159561-A1 | HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES | FMC CORP (US) | 2023-05-25 | — | — | US | disclosed |
| US-11578085-B2 | Heterocycle-substituted bicyclic azole pesticides | FMC CORPORATION (US) | 2023-02-14 | — | — | US | disclosed |
| EP-4105209-A2 | HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES | FMC Corporation (US) | 2022-12-21 | — | — | EP | disclosed |
| EP-3424919-B1 | HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES | FMC CORP (US) | 2022-04-27 | — | — | EP | disclosed |
| US-20210017192-A1 | HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES | FMC CORP (US) | 2021-01-21 | — | — | US | disclosed |
| US-10822351-B2 | Heterocycle-substituted bicyclic azole pesticides | FMC CORPORATION (US) | 2020-11-03 | — | — | US | disclosed |
| US-6900183-B2 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2005-05-31 | — | — | US | disclosed |
| US-20040082526-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-29 | — | — | US | disclosed |
| EP-1343797-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002050092-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-5470862-A | Intravenous anesthetics | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1995-11-28 | — | — | US | disclosed |
| US-4997836-A | Inhibitor of platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0368670-A1 | Trisubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10822351-B2 | Heterocycle-substituted bicyclic azole pesticides | CYP4X1, DDT, CHRM1 | KDM4E 1286/4885RAB9A 2063/4885NPC1 4398/4885 |
| US-20230159561-A1 | HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES | CYP4X1, DDT, CHRM1 | KDM4E 1286/4885RAB9A 2063/4885NPC1 4398/4885 |
| US-11578085-B2 | Heterocycle-substituted bicyclic azole pesticides | CYP4X1, DDT, CHRM1 | KDM4E 1286/4885RAB9A 2063/4885NPC1 4398/4885 |
| US-20040082526-A1 | Macrolide antibiotics | MALT1, MRPL21, CYP51A1 | KDM4E 1616/4885RAB9A 1281/4885NPC1 51/4885 |
| US-20210017192-A1 | HETEROCYCLE-SUBSTITUTED BICYCLIC AZOLE PESTICIDES | CYP4X1, DDT, CHRM1 | KDM4E 1286/4885RAB9A 2063/4885NPC1 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.